Evaluation of nine forms of metabolic syndrome diagnosis as risk for cardiovascular disease: An analysis of isolated and combined metabolic factors

Descripción del Articulo

Background: Metabolic syndrome (MetS) is a pathological condition varying according to the guidelines used, leading to ongoing debate on whether all these forms of defining MetS offer the same level of risk for developing cardiovascular diseases (CVDs). The aim of the study was: 1) to determine the...

Descripción completa

Detalles Bibliográficos
Autores: Orihuela Manrique, Eder Jesus, Vera-Ponce, Victor Juan, Zuzunaga-Montoya, Fiorella E., Vasquez Romero, Luisa Erika Milagros, Loayza-Castro, Joan A., Valladares-Garrido, Mario J., Vigil-Ventura, Enrique, Tapia-Limonchi, Rafael
Formato: artículo
Fecha de Publicación:2024
Institución:Universidad Tecnológica del Perú
Repositorio:UTP-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.utp.edu.pe:20.500.12867/14473
Enlace del recurso:https://hdl.handle.net/20.500.12867/14473
https://doi.org/10.14740/jem945
Nivel de acceso:acceso abierto
Materia:Metabolic syndrome
Heart disease
Public health
https://purl.org/pe-repo/ocde/ford#5.01.00
Descripción
Sumario:Background: Metabolic syndrome (MetS) is a pathological condition varying according to the guidelines used, leading to ongoing debate on whether all these forms of defining MetS offer the same level of risk for developing cardiovascular diseases (CVDs). The aim of the study was: 1) to determine the prevalence of each type of MetS; 2) to assess the association of each type with CVDs over a 5-year follow-up period; and 3) to analyze whether each possible combination of MetS carries the same level of risk for developing CVD in the time above frame. Methods: This study is a secondary analysis of a Peruvian cohort database. The dependent variable was the development of CVD. In contrast, the independent variable was MetS, defined based on nine diagnostic methods: Adult Treatment Panel III (ATPIII), International Diabetes Federation (IDF), World Health Organization (WHO), Joint Interim Statement (JIS), European Group for the Study of Insulin Resistance (EGIR), American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI), American Association of Clinical Endocrinologists (AACE), Latin American Diabetes Association (ALAD), and International Lipid Information Bureau Latin America (ILIBLA). Results were presented as relative risk (RR). Results: The overall prevalence of MetS was 40.59%, while the 5-year incidence of CVD was 1.69%. The lowest prevalence was found with ALAD criteria (5.6%), while the highest was ILIBLA (37%). Diagnostic forms of MetS according to ILIBLA (RR = 5.06; 95% confidence interval (CI): 1.64 - 15.62), AHA/NHLBI (RR = 5.06; 95% CI: 1.64 - 15.62), JIS (RR = 3.66; 95% CI: 1.22 - 10.97), and API (RR = 2.83; 95% CI: 1.11 - 7.20) showed a risk of CVD. Additionally, hyperglycemia, hypertriglyceridemia, and elevated blood pressure were found to be individually associated with the presence of CVD. In contrast, other factors, such as altered waist circumference (WC) and low high-density lipoprotein (HDL), are only associated with an increased risk in combination with other markers.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).